Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biologics Data Protection In Trade Agreements Becoming Key Focus For PhRMA

This article was originally published in The Pink Sheet Daily

Executive Summary

At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.

You may also be interested in...



Biologics Exclusivity: GPhA Making Last Stand Against TPP

The U.S. Generic Pharmaceutical Association and other groups are opposing the Trans-Pacific Partnership requirement that biologics receive 12 years of exclusivity in part because they don’t want Congress to be unable to change it later.

Biologics Exclusivity: GPhA Making Last Stand In Pacific

GPhA, AARP oppose Trans-Pacific Partnership requirement that biologics receive 12 years of exclusivity in part because they don’t want Congress to be unable to change it later.

Asian Free Trade Deal Could Strengthen Canadian Patent Rights, PhRMA Says

Brand industry hopes weaknesses in Canada’s intellectual property regime, including lack of patent term restoration and a higher patent utility standard for biopharmaceutical products, could be addressed through the 11-nation talks on a Trans-Pacific Partnership agreement.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel